Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Active:	No
Cancer Type:	Colon/Rectal Cancer Esophogeal Cancer Stomach/ Gastric Cancer	NCT ID:	NCT03798626
Trial Phases:	Phase I	Protocol IDs:	CVPM087A2101 (primary) NCI-2019-04426 2018-003952-19
Eligibility:	18 - 100 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Novartis Pharmaceuticals Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT03798626

Summary

This study will determine the pharmacodynamically-active dose of gevokizumab and the
tolerable dose of gevokizumab in combination with the standard of care anti-cancer
therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer
and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in
combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.